Assembly Biosciences, Inc. (ASMB) Downgraded to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) from a hold rating to a sell rating in a research report released on Monday.

According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “

Several other analysts also recently issued reports on ASMB. Chardan Capital initiated coverage on Assembly Biosciences in a report on Tuesday, May 30th. They issued a buy rating and a $35.00 price target on the stock. BidaskClub raised Assembly Biosciences from a strong sell rating to a sell rating in a report on Thursday, August 3rd.

Shares of Assembly Biosciences (NASDAQ ASMB) traded up 3.85% during midday trading on Monday, reaching $24.83. The company’s stock had a trading volume of 18,142 shares. The company’s 50-day moving average price is $21.88 and its 200 day moving average price is $22.77. Assembly Biosciences has a 1-year low of $5.85 and a 1-year high of $28.24. The firm’s market capitalization is $431.15 million.

COPYRIGHT VIOLATION NOTICE: “Assembly Biosciences, Inc. (ASMB) Downgraded to Sell at Zacks Investment Research” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2017/08/15/assembly-biosciences-inc-asmb-downgraded-to-sell-at-zacks-investment-research.html.

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in shares of Assembly Biosciences by 21.2% in the second quarter. Vanguard Group Inc. now owns 610,916 shares of the biopharmaceutical company’s stock valued at $12,615,000 after buying an additional 107,065 shares during the last quarter. State Street Corp acquired a new stake in shares of Assembly Biosciences during the second quarter valued at $4,234,000. Northern Trust Corp increased its stake in shares of Assembly Biosciences by 221.2% in the second quarter. Northern Trust Corp now owns 195,321 shares of the biopharmaceutical company’s stock valued at $4,033,000 after buying an additional 134,513 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Assembly Biosciences during the second quarter valued at $3,426,000. Finally, Lyon Street Capital LLC increased its stake in shares of Assembly Biosciences by 352.6% in the second quarter. Lyon Street Capital LLC now owns 136,200 shares of the biopharmaceutical company’s stock valued at $2,813,000 after buying an additional 106,107 shares during the last quarter. 68.88% of the stock is currently owned by hedge funds and other institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Assembly Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Assembly Biosciences Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit